Clinical trial
A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
NCT00069121 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00069121 |
|---|---|
| Title | A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer |
| Official title | An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Fluorouracil/Leucovorin as Adjuvant Therapy for Patients Who Have Undergone Surgery for Colon Carcinoma, AJCC/UICC Stage III (Dukes Stage C) |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) |
| Enrollment | 1,886 |
| Start date | Apr 18, 2003 |
| Primary completion | Apr 21, 2011 |
| Completion | Apr 21, 2011 |
| First posted | Sep 18, 2003 |
| Last update posted | Mar 6, 2020 |
| Countries | Australia, Belgium, Brazil, Canada, China, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland and 17 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: